On the other hand, the therapeutic value of determining the BRAF status in CM is increasingly supported by recent studies reporting the beneficial effects of combined BRAF/MEK inhibition in the treatment of recurrent or metastatic CM [52,53,54,55,56] or as neoadjuvant therapy for primary CM [32], and by those recommending its future testing in adjuvant settings [57,58]. This evidence concerns the gene MAP2K7 and cutaneous mastocytosis.